{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:34:34Z","timestamp":1761896074012,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Millennium Pharmaceuticals"},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.bbmt.2015.05.024","type":"journal-article","created":{"date-parts":[[2015,5,30]],"date-time":"2015-05-30T04:42:34Z","timestamp":1432960954000},"page":"1921-1925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tbo-Filgrastim versus Filgrastim during Mobilization and\u00a0Neutrophil Engraftment for Autologous Stem Cell\u00a0Transplantation"],"prefix":"10.1016","volume":"21","author":[{"given":"Mohammed M.","family":"Elayan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin G.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Magraner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-3864","authenticated-orcid":false,"given":"Paul J.","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Bachier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.05.024_bib1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.05.024_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.05.024_bib3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","article-title":"Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"17","author":"Lazarus","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.05.024_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1537-2995.1997.37997454014.x","article-title":"Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients","volume":"37","author":"Weaver","year":"1997","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2015.05.024_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/bmt.2011.73","article-title":"Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia","volume":"47","author":"Mahindra","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1537-2995.2006.00699.x","article-title":"A\u00a0single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma","volume":"46","author":"Bruns","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2015.05.024_bib7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/bmt.2009.59","article-title":"Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT","volume":"43","author":"Kobbe","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib8","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"Dipersio","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.05.024_bib9","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"Dipersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.05.024_bib10","first-page":"217","article-title":"Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF","volume":"3","author":"Weisdorf","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.blre.2012.09.003","article-title":"Advances in stem cell mobilization","volume":"26","author":"Motabi","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2015.05.024_bib12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/bmt.2013.80","article-title":"Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone","volume":"48","author":"Sung","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","article-title":"Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization","volume":"19","author":"Micallef","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib14","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","article-title":"How I treat patients who mobilize hematopoietic stem cells poorly","volume":"118","author":"To","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.05.024_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood.V67.2.529.529","article-title":"Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma","volume":"67","author":"K\u00f6rbling","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.05.024_bib16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2141.1985.tb02888.x","article-title":"Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy","volume":"61","author":"Juttner","year":"1985","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.05.024_bib17","first-page":"442","article-title":"Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood","volume":"18","author":"To","year":"1990","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.05.024_bib18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12325-011-0009-1","article-title":"First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor","volume":"28","author":"Lefr\u00e8re","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.bbmt.2015.05.024_bib20","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/bmt.2012.270","article-title":"Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors","volume":"48","author":"Schmitt","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.transci.2013.04.007","volume":"48","author":"Sivgin","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bbmt.2015.05.024_bib22","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/j.bbmt.2014.11.670","article-title":"Tbo or not tbo \u2013 that is the question!","volume":"21","author":"Trifilio","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib23","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/j.bbmt.2013.12.434","article-title":"The use of Tevagrastim (biosimilar filgrastim XMO2) for hematopoietic stem cell mobilization in HLA matched sibling donors for allogenic stem cell transplantation to AML\/MDS patients","volume":"20","author":"Danylesko","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.024_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/2040620714565962","article-title":"Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant","volume":"6","author":"Uddin","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.bbmt.2015.05.024_bib25","article-title":"Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens","author":"Bassi","year":"2015","journal-title":"Blood Transfus"},{"key":"10.1016\/j.bbmt.2015.05.024_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.13199","article-title":"Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from\u00a0the Rome Transplant Network","volume":"169","author":"Marchesi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.05.024_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12325-014-0114-z","article-title":"Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF","volume":"31","author":"Rem\u00e9nyi","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.bbmt.2015.05.024_bib28","unstructured":"Weiss KD. \u201cBL 103353\/5001.\u201d Letter to Jeffrey N. Fellows. 29 May 2002. Department of Health and Human Services. Food and Drug Administration, n.d. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2002\/filgamg052902L.pdf. Accessed May 1,\u00a02015."},{"key":"10.1016\/j.bbmt.2015.05.024_bib29","unstructured":"Traynor, K. FDA approves Teva's Tbo-filgrastim. American Society of Health-System Pharmacists. Available at: http:\/\/www.ashp.org\/menu\/News\/PharmacyNews\/NewsArticle.aspx?id=3775. Updated October 21, 2013. Accessed January 28,\u00a02015."},{"key":"10.1016\/j.bbmt.2015.05.024_bib30","unstructured":"U.S. Food and Drug Administration. FDA approves new treatment for severe neutropenia in certain cancer patients. www.fda.gov. FDA, 29 Aug. 2012. Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm317392.htm. Updated August 31, 2012. Accessed May 1,\u00a02015."},{"key":"10.1016\/j.bbmt.2015.05.024_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/10428190902756081","article-title":"XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy","volume":"50","author":"Engert","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2015.05.024_bib32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/JTO.0b013e3181a52964","article-title":"XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy","volume":"4","author":"Gatzemeier","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.bbmt.2015.05.024_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000232580","article-title":"Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma","volume":"32","author":"Engert","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.bbmt.2015.05.024_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00063030-200923010-00005","article-title":"Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial","volume":"23","author":"Lubenau","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.bbmt.2015.05.024_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5414\/CPP47275","article-title":"Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers","volume":"47","author":"Lubenau","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2015.05.024_bib36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1160\/TH10-08-0530","article-title":"Increased platelet aggregation and in\u00a0vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial","volume":"105","author":"Spiel","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bbmt.2015.05.024_bib37","first-page":"75","article-title":"Biosimilars: new promise for reducing healthcare costs","volume":"28","author":"Munsch","year":"2014","journal-title":"J\u00a0Biomed Res"},{"key":"10.1016\/j.bbmt.2015.05.024_bib38","unstructured":"Biosimilars. U.S. Food and Drug Administration. Available at: http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/approvalapplications\/therapeuticbiologicapplications\/biosimilars\/default.htm. Updated January 2, 2015. Accessed January 28,\u00a02015."},{"key":"10.1016\/j.bbmt.2015.05.024_bib39","unstructured":"U.S. Food and Drug Administration. FDA approves first biosimilar product Zarxio. www.fda.gov. FDA, March 6, 2015. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm436648.htm. Accessed May 1,\u00a02015."},{"key":"10.1016\/j.bbmt.2015.05.024_bib40","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3324\/haematol.2011.045740","article-title":"Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association","volume":"96","author":"Shaw","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.05.024_bib41","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2011.041210","article-title":"Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation","volume":"96","author":"Barosi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.05.024_bib42","first-page":"550","article-title":"Ethical issues and concerns about the use\u00a0of\u00a0biosimilar granulocyte colony-stimulating factors for the mobilisation of stem cells in normal donors","volume":"10","author":"Liumbruno","year":"2012","journal-title":"Blood Transfus"},{"key":"10.1016\/j.bbmt.2015.05.024_bib43","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","article-title":"Biosimilars: the science of extrapolation","volume":"124","author":"Weise","year":"2014","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500381X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500381X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:58Z","timestamp":1761058318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911500381X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S108387911500381X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.024","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tbo-Filgrastim versus Filgrastim during Mobilization and\u00a0Neutrophil Engraftment for Autologous Stem Cell\u00a0Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}